natgillin/translations-raw huggingface dataset:
It is recommended that INR (international normalised ratio) be monitored.
Priporočljivo je nadziranje INR (mednarodnega normaliziranega razmerja).
Anticonvulsants (phenobarbital, phenytoin, carbamazepine): will induce CYP3A4 and may decrease lopinavir concentrations.
Antiepileptiki (fenobarbital, fenitoin, karbamazepin): inducirajo CYP3A4 in lahko zmanjšajo koncentracijo lopinavirja.
In addition, co-administration of phenytoin and lopinavir/ ritonavir resulted in moderate decreases in steady-state phenytoin concentrations.
Poleg tega je sočasna uporaba fenitoina in kombinacije lopinavir/ ritonavir povzročila zmerno zmanjšanje koncentracije fenitoina v stanju dinamičnega ravnovesja.
Phenytoin levels should be monitored when co-administering with lopinavir/ ritonavir.
Med sočasno uporabo kombinacije lopinavir/ ritonavir morate kontrolirati koncentracijo fenitoina.
8 Bupropion: in healthy volunteers, the AUC and Cmax of bupropion and of its active metabolite, hydroxybupropion, were decreased by about 50% when co-administered with lopinavir/ ritonavir capsules 400/ 100 mg twice daily at steady-state.
Med sočasno uporabo kapsul lopinavirja/ ritonavirja 400/ 100 mg dvakrat na dan sta se AUC in Cmax bupropiona in njegovega aktivnega presnovka hidroksibupropiona pri zdravih prostovoljcih v stanju dinamičnega ravnovesja zmanjšali za okoli 50%.
Therefore, if the co-administration of lopinavir/ ritonavir with bupropion is judged unavoidable, this should be done under close clinical monitoring for bupropion efficacy, without exceeding the recommended dosage, despite the observed induction.
Če presodite, da je sočasna uporaba lopinavirja/ ritonavirja z bupropionom neizogibna, morate med sočasno uporabo teh zdravil natančno klinično spremljati učinkovitost bupropiona in kljub opaženi indukciji ne smete preseči priporočenega odmerka.
Trazodone: in a pharmacokinetic study performed in healthy volunteers, concomitant use of low dose ritonavir (200 mg twice daily) with a single dose of trazodone led to an increase in plasma concentrations of trazodone (AUC increased by 2.4 fold).
V študiji farmakokinetike pri zdravih prostovoljcih je sočasna uporaba nizkega odmerka ritonavirja (200 mg dvakrat na dan) s posamičnim odmerkom trazodona zvišala koncentracijo trazodona v plazmi (AUC se je povečala za 2, 4- krat).
Adverse events of nausea, dizziness, hypotension and syncope were observed following co-administration of trazodone and ritonavir in this study.
Po sočasni uporabi trazodona in ritonavirja so v tej študiji opazili naslednje neželene učinke: navzejo, omotico, hipotenzijo in sinkopo.
However, it is unknown whether the combination of lopinavir/ ritonavir cause a similar increase in trazodone exposure.
Ni znano, ali lahko tudi kombinacija lopinavir/ ritonavir podobno poveča izpostavljenost trazodonu.
The combination should be used with caution and a lower dose of trazodone should be considered.
Kombinacijo uporabljajte previdno; v poštev pride zmanjšanje odmerka trazodona.
Digoxin: plasma concentrations of digoxin may be increased when co-administered with Kaletra.
Med sočasno uporabo z zdravilom Kaletra se lahko koncentracija digoksina v plazmi zviša.
Particular caution should be used when prescribing Kaletra in patients taking digoxin as the acute inhibitory effect of ritonavir on Pgp is expected to significantly increase digoxin levels.
Posebna previdnost je potrebna pri predpisovanju zdravila Kaletra bolnikom, ki jemljejo digoksin, kajti pričakovati je treba, da akutno zaviralno delovanje ritonavirja na PgP občutno zviša koncentracijo digoksina.
The increased digoxin level may lessen over time as Pgp induction develops.
Zvišanje koncentracije digoksina se lahko sčasoma zmanjša, ko se razvije indukcija PgP.
Initiation of digoxin in patients already taking Kaletra is expected to result in lower increase of digoxin concentrations.
Pričakovati je mogoče, da uvedba digoksina pri bolnikih, ki že jemljejo zdravilo Kaletra, doseže manjši porast koncentracije digoksina.
Dihydropyridine calcium channel blockers:
Dihidropiridinski zaviralci kalcijevih kanalčkov (npr. felodipin, nifedipin, nikardipin):
(e. g. felodipine, nifedipine, nicardipine): may have their serum concentrations increased by Kaletra.
Zdravilo Kaletra lahko zveča njihovo koncentracijo v serumu.
Lipid lowering agents:
Zdravila za zniževanje ravni lipidov:
HMG-CoA reductase inhibitors which are highly dependent on CYP3A4 metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with Kaletra.
Pri zaviralcih reduktaze HMG- CoA, ki so zelo odvisni od presnove s CYP3A4 (npr. lovastatin in simvastatin), je med sočasno uporabo z zdravilom Kaletra treba pričakovati izrazito zvečanje njihove koncentracije v plazmi.
Since increased concentrations of HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis, the combination of these medicinal products with Kaletra is not recommended.
Zvečana koncentracija zaviralcev reduktaze HMG- CoA lahko povzroči miopatijo, vključno z rabdomiolizo, zato njihovo kombiniranje z zdravilom Kaletra ni priporočljivo.
When atorvastatin was given concurrently with Kaletra, a mean 4.7-fold and 5.9-fold increase in atorvastatin Cmax and AUC, respectively, was observed.
Ko so atorvastatin uporabili hkrati z zdravilom Kaletra, so opažali v povprečju 4, 7- kratno zvečanje Cmax in 5, 9- kratno zvečanje AUC atorvastatina.
When used with Kaletra, the lowest possible dose of atorvastatin should be administered.
Med uporabo z zdravilom Kaletra je treba uporabiti najmanjši možni odmerek atorvastatina.
Rosuvastatin is not dependent on CYP3A.
Rosuvastatin ni odvisen od CYP3A.
However, when given concurrently with Kaletra a mean 5-fold and 2-fold increase in rosuvastatin Cmax and AUC, respectively, was observed.
Toda med sočasno uporabo rosuvastatina in zdravila Kaletra so opažali v povprečju 5- kratno povečanje Cmax in 2- kratno povečanje AUC rosuvastatina.
Caution should be exercised when Kaletra is co-administered with rosuvastatin.
Previdnost je potrebna, kadar zdravilo Kaletra uporabljate hkrati z rosuvastatinom.
Results from an interaction study with Kaletra and pravastatin reveal no clinically significant interaction.
Rezultati interakcijske raziskave z zdravilom Kaletra in pravastatinom ne kažejo klinično pomembnega medsebojnega delovanja.
The metabolism of pravastatin and fluvastatin is not dependent on CYP3A4, and interactions are not expected with Kaletra.
Presnova pravastatina in fluvastatina ni odvisna od CYP3A4 in medsebojnega delovanja z zdravilom Kaletra ni pričakovati.
If treatment with a HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.
Če je indicirano zdravljenje z zaviralcem reduktaze HMG- CoA, sta priporočljiva pravastatin ali fluvastatin.
Dexamethasone: may induce CYP3A4 and may decrease lopinavir concentrations.
9 Deksametazon: lahko inducira CYP3A4 in zmanjša koncentracijo lopinavirja.
Phosphodiesterase inhibitors: phosphodiesterase inhibitors which are dependent on CYP3A4 metabolism, such as tadalafil and sildenafil, are expected to result in an approximately 2-fold and 11-fold increase in AUC respectively, when co-administered with ritonavir containing regimens including Kaletra and may result in an increase in PDE5 inhibitor associated adverse reactions including hypotension, synope, visual changes and prolonged erection.
Posledica je lahko porast neželenih učinkov, povezanih z zaviralci PDE5, med drugim hipotenzije, sinkope, sprememb vida in dolgotrajne erekcije.
Particular caution must be used when prescribing sildenafil or tadalafil in patients receiving Kaletra with increased monitoring for adverse events.
Bolnikom, ki jemljejo zdravilo Kaletra, morate sildenafil oz. tadalafil predpisovati posebno previdno in jih pogosteje nadzorovati glede neželenih učinkov.
Co-administration of vardenafil with rtionavir containing regimens including Kaletra is expected to result in 49-fold increase in vardenafil AUC.
Pričakovati je, da sočasna uporaba vardenafila s shemami, ki vključujejo ritonavir (vključno z zdravilom Kaletra), povzroči 49- kratno povečanje AUC vardenafila.
The use of vardenafil with Kaletra is contraindicated (see section 4.3).
Uporaba vardenafila z zdravilom Kaletra je kontraindicirana (glejte poglavje 4. 3).
Cyclosporin, sirolimus (rapamycin) and tacrolimus: concentrations may be increased when co-administered with Kaletra.
Ciklosporin, sirolimus (rapamicin) in takrolimus: med sočasno uporabo z zdravilom Kaletra se njihova koncentracija lahko zveča.
More frequent therapeutic concentration monitoring is recommended until plasma levels of these products have been stabilised.
Dokler se koncentracija teh zdravil v plazmi ne stabilizira, je priporočljivo pogostejše kontroliranje terapevtske koncentracije.
9 Ketoconazole and itraconazole: may have serum concentrations increased by Kaletra.
Zdravilo Kaletra lahko zveča njuno koncentracijo v serumu.
High doses of ketoconazole and itraconazole (> 200 mg/ day) are not recommended.
Veliki odmerki ketokonazola in itrakonazola (> 200 mg/ dan) niso priporočljivi.
Voriconazole: due to the potential for reduced voriconazole concentrations, co-administration of voriconazole and low dose ritonavir (100 mg twice daily) as contained in Kaletra should be avoided unless an assessment of the benefit/ risk to patient justifies the use of voriconazole.
Zaradi možnega zmanjšanja koncentracije vorikonazola se je treba izogniti sočasni uporabi vorikonazola in nizkih odmerkov ritonavirja (100 mg dvakrat na dan), kot jih vsebuje zdravilo Kaletra, razen če ocena koristi in tveganja pri bolniku upravičuje uporabo vorikonazola.
Clarithromycin: moderate increases in clarithromycin AUC are expected when co-administered with Kaletra.
Klaritromicin: če je klaritromicin uporabljen hkrati z zdravilom Kaletra, je treba pričakovati zmerno zvečanje njegove AUC.
For patients with renal or hepatic impairment dose reduction of clarithromycin should be considered (see section 4.4).
Pri bolnikih z okvaro ledvic ali jeter je treba razmisliti o zmanjšanju odmerka klaritromicina (glejte poglavje 4. 4).
Buprenorphine: buprenorphine (dosed at 16 mg daily) co-administered with lopinavir/ ritonavir (dosed at 400/ 100 mg twice daily) showed no clinically significant interaction.
Med sočasno uporabo buprenorfina (v odmerku 16 mg na dan) in kombinacije lopinavir/ ritonavir (v odmerku 400/ 100 mg dvakrat na dan) niso ugotovili klinično pomembnega medsebojnega delovanja.
Kaletra can be co-administered with buprenorphine with no dose adjustment.
Zdravilo Kaletra lahko uporabite sočasno z buprenorfinom brez prilagoditve odmerka.
Kaletra was demonstrated to lower plasma concentrations of methadone.
Zdravilo Kaletra dokazano zmanjša koncentracijo metadona v plazmi.
Monitoring plasma concentrations of methadone is recommended.
Priporočljivo je nadziranje koncentracije metadona v plazmi.
Contraceptives: levels of ethinyl oestradiol were decreased when oestrogen-based oral contraceptives were co-administered with Kaletra.
Ob sočasni uporabi estrogenskih peroralnih kontraceptivov in zdravila Kaletra se je koncentracija etinilestradiola zmanjšala.
In case of co-administration of Kaletra with contraceptives containing ethinyl oestradiol (whatever the contraceptive formulation e. g. oral or patch), alternative methods of contraception are to be used.
Med sočasno uporabo zdravila Kaletra s kontraceptivi, ki vsebujejo etinilestradiol (ne glede na formulacijo kontraceptiva, npr. peroralni ali obliž), je treba uporabiti druge načine kontracepcijske zaščite.
Rifabutin: when rifabutin and Kaletra were co-administered for 10 days, rifabutin (parent substance and active 25-O-desacetyl metabolite) Cmax and AUC were increased by 3.5- and 5.7-fold, respectively.
Rifabutin: med 10- dnevno sočasno uporabo rifabutina in zdravila Kaletra, se je Cmax rifabutina (matične spojine in aktivnega 25- O- dezacetilnega presnovka) zvečala za 3, 5- krat, AUC pa za 5, 7- krat.
On the basis of these data, a rifabutin dose reduction of 75% (i. e.
Na podlagi teh podatkov je med hkratno uporabo rifabutina in zdravila Kaletra priporočljivo 75% zmanjšanje odmerka rifabutina (t. j.
150 mg every other day or 3 times per week) is recommended when administered with Kaletra.
150 mg vsak drugi dan ali 3- krat na teden).
Further reduction may be necessary.
Potrebno utegne biti še nadaljnje zmanjšanje.
Rifampicin: co-administration of Kaletra with rifampicin is not recommended.
Rifampicin: sočasna uporaba zdravila Kaletra in rifampicina ni priporočljiva.
Rifampicin administered with Kaletra causes large decreases in lopinavir concentrations which may in turn significantly decrease the lopinavir therapeutic effect.
Uporaba rifampicina z zdravilom Kaletra povzroči veliko zmanjšanje koncentracij lopinavirja, s posledičnim pomembnim zmanjšanjem terapevtskega učinka lopinavirja.
A dose adjustment of Kaletra 400 mg/ 400 mg twice daily has allowed compensating for the CYP 3A4 inducer effect of rifampicin.
Prilagoditev odmerka zdravila Kaletra 400 mg/ 400 mg dvakrat na dan kompenzira inducibilni učinek rifampicina na CYP3A4.
However, such a dose adjustment might be associated with ALT/ AST elevations and with increase in gastrointestinal disorders.
Vendar je taka prilagoditev odmerka lahko povezana z zvišanjem ALT/ AST in s povečanjem bolezni prebavil.
Therefore, this co-administration should be avoided unless judged strictly necessary.
Zato naj se taka sočasna uporaba izogiba, razen če se presodi, da je absolutno potrebna.
If this co-administration is judged unavoidable, increased dose of Kaletra at 400 mg/ 400 mg twice daily may be administered with rifampicin under close safety and therapeutic drug monitoring.
Če se presodi, da je taka sočasna uporaba neizogibna, se uporabi povečan odmerek zdravila Kaletra in sicer 400 mg/ 400 mg dvakrat dnevno sočasno z rifampicinom pod skrbno varnostno in terapevtsko kontrolo.
The Kaletra dose should be titrated upward only after rifampicin has been initiated(see section 4.4).
Dvigajoče titriranje odmerka zdravila Kaletra se lahko prične šele po začetku jemanja rifampicina (glejte poglavje 4. 4).
St John’ s wort: serum levels of lopinavir and ritonavir can be reduced by concomitant use of the herbal preparation St John’ s wort (Hypericum perforatum).
10 Šentjanževka: sočasna uporaba zeliščnih pripravkov šentjanževke (Hypericum perforatum) lahko zmanjša koncentracijo lopinavirja in ritonavirja v serumu.
This is due to the induction of drug metabolising enzymes by St John’ s wort.
To je posledica indukcije encimov, ki presnavljajo zdravila, s šentjanževko.
Herbal preparations containing St John’ s wort should therefore not be combined with lopinavir and ritonavir.
Zeliščnih izdelkov, ki vsebujejo šentjanževko, se zato ne sme kombinirati z lopinavirjem in ritonavirjem.
If a patient is already taking St John’ s wort, stop St John’ s wort and if possible check viral levels.
Če bolnik že jemlje šentjanževko, njeno jemanje prekinite in, če je mogoče, kontrolirajte raven virusov.
Lopinavir and ritonavir levels may increase on stopping St John’ s wort.
Koncentraciji lopinavirja in ritonavirja se lahko po prekinitvi šentjanževke zvečata.
The dose of Kaletra may need adjusting.
Potrebna utegne biti prilagoditev odmerka zdravila Kaletra.
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’ s wort (see section 4.3).
Indukcijski učinek lahko traja še vsaj 2 tedna po prenehanju zdravljenja s šentjanževko (glejte poglavje 4. 3).
Midazolam: midazolam is extensively metabolised by CYP3A4.
Midazolam: midazolam se izdatno presnovi s CYP3A4.
Co-administration with Kaletra may cause a large increase in the concentration of this benzodiazepine.
Sočasna uporaba zdravila Kaletra lahko močno zviša koncentracijo tega benzodiazepina.
A phenotyping cocktail study in 14 healthy volunteers showed an increase of AUC by about 13 fold with oral midazolam and an increase by about 4 fold with parenteral midazolam.
Fenotipizacijska koktajl- študija pri 14 zdravih prostovoljcih je pokazala približno 13- kratno povečanje AUC ob peroralni uporabi midazolama in približno 4- kratno povečanje AUC ob uporabi parenteralnega midazolama.
Therefore, Kaletra should not be co-administered with orally administered midazolam (see section 4.3), whereas caution should be used with co-administration of Kaletra and parenteral midazolam.
Zato zdravila Kaletra ne smete uporabljati sočasno s peroralnim midazolamom (glejte poglavje 4. 3), v primeru sočasne uporabe zdravila Kaletra in parenteralnega midazolama pa morate biti previdni.
If Kaletra is co-administered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/ or prolonged sedation.
Če zdravilo Kaletra uporabite sočasno s parenteralnim midazolamom, morate to napraviti v enoti za intenzivno nego (EIN) ali podobnem okolju, ki omogoča natančno klinično spremljanje in ustrezno medicinsko ukrepanje v primeru depresije dihanja in/ ali dolgotrajne sedacije.
10 Fluticasone propionate (interaction with ritonavir): in a clinical study where ritonavir 100 mg capsules twice daily were co − administered with 50 μ g intranasal fluticasone propionate (4 times daily) for seven days in healthy subjects, the fluticasone propionate plasma levels increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% confidence interval 82 − 89%).
Flutikazonpropionat (interakcija z ritonavirjem): pri zdravih osebah, ki so med klinično študijo 7 dni sočasno prejemale ritonavir v obliki 100 mg kapsul dvakrat dnevno in flutikazonpropionat v odmerku 50 µg intranazalno (4- krat dnevno), so ugotovili, da so se vrednosti flutikazonpropionata v plazmi znatno povečale, intrinzične vrednosti kortizola pa zmanjšale za približno 86% (90% interval zaupanja; 82- 89%).
Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway eg budesonide.
Pri bolnikih, ki so prejemali ritonavir in inhalacijske ali intranazalne oblike flutikazonpropionata, so poročali o pojavu sistemskih kortikosteroidnih učinkov, vključno s Cushingovim sindromom in z zaviralnim vplivom na nadledvično žlezo.
Consequently, concomitant administration of Kaletra and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects (see section 4.4).
Omenjeni sistemski kortikosteroidni učinki se lahko pojavijo tudi pri uporabi drugih kortikosteroidov, ki se presnavljajo s P450 3A, npr. budezonid, zato sočasne uporabe zdravila Kaletra in tovrstnih glukokortikoidov ne priporočamo, razen v primerih, ko možne koristi zdravljenja prevladajo nad tveganjem za pojav sistemskih kortikosteroidnih učinkov (glejte poglavje 4. 4).
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (eg beclomethasone).
Razmisliti je treba o zmanjšanju odmerka glukokortikoida ob sočasnem skrbnem nadziranju lokalnih in sistemskih učinkov ali o zamenjavi z glukokortikoidom, ki ni substrat za CYP3A4 (npr. beklometazon).
Based on known metabolic profiles, clinically significant interactions are not expected between Kaletra and fluvastatin, dapsone, trimethoprim/ sulfamethoxazole, azithromycin or fluconazole.
Na podlagi znanih presnovnih značilnosti ni pričakovati klinično pomembnega medsebojnega delovanja zdravila Kaletra in fluvastatina, dapsona, trimetoprima/ sulfametoksazola, azitromicina ali flukonazola.
There are no data from the use of Kaletra in pregnant women.
Ni podatkov o uporabi zdravila Kaletra pri nosečnicah.
Kaletra should not be used during pregnancy unless clearly necessary.
Zdravila Kaletra ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
HIV infected women must not breast-feed their infants under any circumstances to avoid transmission of HIV.
S HIV okužene ženske nikakor ne smejo dojiti, da ne pride do prenosa HIV na otroka.
Patients should be informed that nausea has been reported during treatment with Kaletra (see section 4.8).
Bolnikom morate povedati, da so poročali o navzeji med zdravljenjem z zdravilom Kaletra (glejte poglavje 4. 8).
The safety of Kaletra has been investigated in 612 patients in Phase II/ III clinical trials, of which 442 have received a dose of 400/ 100 mg (3 capsules) twice daily.
Varnost zdravila Kaletra so raziskali pri 612 bolnikih v kliničnih preskušanjih II. in III. faze; 442 teh bolnikov je dobivalo odmerek 400/ 100 mg (3 kapsule) dvakrat na dan.
In some studies, Kaletra was used in combination with efavirenz or nevirapine.
V nekaterih študijah so zdravilo Kaletra uporabili v kombinaciji z efavirenzem ali nevirapinom.
The most common adverse event associated with Kaletra therapy was diarrhoea and was generally of mild to moderate severity.
Najpogostejši neželen pojav, povezan z zdravljenjem z zdravilom Kaletra, je bila driska, ki je bila praviloma blaga do zmerna.
Discontinuation due to adverse reactions was 4.5% (naïve patients) and 9% (experienced patients) over a 48 week period.
9% (izkušeni bolniki).
Furthermore, rare increases in PR interval have been reported during Kaletra therapy (see section 4.4: sections pancreatitis and lipid elevations).
Poleg tega so med zdravljenjem z zdravilom Kaletra opisani redki primeri podaljšanja intervala PR (glejte poglavje 4. 4: odstavka o pankreatitisu in zvišanju lipidov).
Increased CPK, myalgia, myositis, and rarely, rhabdomyolysis have been reported with protease inhibitors, particularly in combination with nucleoside reverse transcriptase inhibitors.
Med uporabo zaviralcev proteaz so, zlasti v kombinaciji z nukleozidnimi zaviralci reverzne transkriptaze, poročali o zvišanju CPK, mialgiji, miozitisu in, redko, rabdomiolizi.
Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV patients including the loss of peripheral and facial subcutaneous fat, increased intra-abdominal and visceral fat, breast hypertrophy and dorsocervical fat accumulation (buffalo hump).
Pri bolnikih, okuženih s HIV, je bilo kombinirano protiretrovirusno zdravljenje povezano s prerazporeditvijo telesnega maščevja (lipodistrofijo), vključno z izgubo podkožnega maščevja periferno in na obrazu, zvečanjem intraabdominalnega in visceralnega maščevja, hipertrofijo prsi in dorzocervikalnim kopičenjem maščevja (bivolja grba).
11 Combination antiretroviral therapy has been associated with metabolic abnormalities such as hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia and hyperlactataemia (see section 4.4).
Kombinirano protiretrovirusno zdravljenje je bilo povezano s presnovnimi nepravilnostmi, npr. hipertrigliceridemijo, hiperholesterolemijo, odpornostjo proti insulinu, hiperglikemijo in hiperlaktatemijo (glejte poglavje 4. 4).
Adverse reactions:
Neželeni učinki:
The following adverse reactions of moderate to severe intensity with possible or probable relationship to Kaletra have been reported.
Opisani so bili naslednji zmerni do hudi neželeni dogodki, ki so morda ali verjetno povezani z zdravilom Kaletra.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness: very common > 1/ 10, common > 1/ 100 ,< 1/10, uncommon > 1/ 1000, < 1/ 100.
V razvrstitvah pogostnosti so neželeni učinki navedeni po padajoči resnosti: zelo pogosto > 1/ 10, pogosto > 1/ 100, < 1/ 10, občasno > 1/ 1000, < 1/ 100.
Undesirable effects in clinical studies in adult patients Infections and infestations
Infekcijske in parazitske bolezni
Otitis media, bronchitis, sinusitis, furunculosis, bacterial infection, viral infections
vnetje srednjega ušesa, bronhitis, sinuzitis, furunkuloza, bakterijska okužba, virusna okužba
Skin benign neoplasm, cyst
benigna neoplazma kože, cista
Anaemia, leucopenia and lymphadenopathy
anemija, levkopenija in limfadenopatija